Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

IMP3 Expression in Borderline Tumors of the Ovary.

El-Balat A, Sänger N, Karn T, Becker S, Holtrich U, Muallem Z, Arsenic R.

Anticancer Res. 2017 Feb;37(2):583-588.

PMID:
28179304
2.
3.

Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.

Oktem G, Sanci M, Bilir A, Yildirim Y, Kececi SD, Ayla S, Inan S.

Int J Gynecol Cancer. 2012 Jan;22(1):23-9. doi: 10.1097/IGC.0b013e31823228b2.

PMID:
22080880
4.

The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z.

Am J Surg Pathol. 2008 Feb;32(2):304-15. doi: 10.1097/PAS.0b013e3181483ff8.

PMID:
18223334
5.
6.

TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.

El-Balat A, Schmeil I, Karn T, Becker S, Sänger N, Holtrich U, Arsenic R.

Pathol Oncol Res. 2018 Apr;24(2):277-282. doi: 10.1007/s12253-017-0240-4. Epub 2017 May 3.

PMID:
28470574
7.

IMP3 expression in human ovarian cancer is associated with improved survival.

Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Röske A, Müller B, Dietel M, Denkert C.

Int J Gynecol Pathol. 2009 May;28(3):203-10. doi: 10.1097/PGP.0b013e318189a724.

PMID:
19620937
8.

IMP3 expression in serous tumors of the ovary.

Chisté M, Alexis J, Recine M.

Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):658-62. doi: 10.1097/PAI.0000000000000021.

PMID:
25279713
9.
11.

Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.

Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH, An HJ.

Int J Gynecol Pathol. 2011 May;30(3):205-17. doi: 10.1097/PGP.0b013e3182063e71.

PMID:
21464733
12.

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.

Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB.

Mod Pathol. 2009 Mar;22(3):469-75. doi: 10.1038/modpathol.2008.206. Epub 2009 Jan 9.

13.

The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.

Saied EM, El-Etreby NM.

Ann Diagn Pathol. 2017 Apr;27:62-68. doi: 10.1016/j.anndiagpath.2017.01.006. Epub 2017 Jan 22.

PMID:
28325363
14.

Mucinous tumors of the ovary: a review.

Hart WR.

Int J Gynecol Pathol. 2005 Jan;24(1):4-25. Review.

PMID:
15626914
15.

Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Elias KM, Labidi-Galy SI, Vitonis AF, Hornick JL, Doyle LA, Hirsch MS, Cramer DW, Drapkin R.

Gynecol Oncol. 2014 Feb;132(2):328-33. doi: 10.1016/j.ygyno.2013.12.011. Epub 2013 Dec 14.

16.

The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.

Lu L, Wang S, Zhu Q, Qu Y, Gu W, Ning Y, Chen X, Wang Y.

Pathol Res Pract. 2018 Aug;214(8):1087-1094. doi: 10.1016/j.prp.2018.05.026. Epub 2018 May 29.

17.

RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma.

Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, Hsu HC.

Hepatology. 2008 Oct;48(4):1118-27. doi: 10.1002/hep.22459.

PMID:
18802962
18.
19.

Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.

Morimatsu K, Aishima S, Yamamoto H, Hayashi A, Nakata K, Oda Y, Shindo K, Fujino M, Tanaka M, Oda Y.

Hum Pathol. 2013 Sep;44(9):1714-21. doi: 10.1016/j.humpath.2012.12.020. Epub 2013 Apr 15.

PMID:
23597774
20.

HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network.

Nassir M, Darb-Esfahani S, Richter R, Chekerov R, Hall C, Muallem MZ, Denkert C, Stamatian F, Fotopoulou C, Sehouli J, Braicu EI.

Anticancer Res. 2013 Apr;33(4):1673-7.

PMID:
23564814

Supplemental Content

Support Center